Collaboration Agreements (Details) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2022	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common shares, Issued				51,634,752	35,012,125
Revenue				$ 18,437,000	$ 32,166,000
Accounts receivable				2,765,000	1,822,000
Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				18,437,000	32,166,000
Neurocrine Biosciences [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable				2,184,000
Neurocrine Biosciences [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				10,167,000	32,166,000
Milestone payments				5,270,000
Neurocrine Biosciences [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					25,926,000
Neurocrine Biosciences [Member] | Development Services Under the Initial Development Program for the DTCs [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				3,715,000	884,000
Neurocrine Biosciences [Member] | Research And Development Funding | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 6,452,000	$ 5,356,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from upfront fee			$ 50,000,000
Upfront payment received in cash			30,000,000			$ 30,000,000
Upfront payment received in equity investment			20,000,000			20,000,000
Potential Milestone Payments Receivable			1,667,500,000			1,667,500,000
Percentage of option to co-fund development costs upon achievement of certain milestones				50.00%
Collaborate agreement premium related to equity investment						3,333,000
Transaction price allocated to performance obligations						33,333,000
Variable consideration allocated to performance obligation				$ 592,000
Milestone Payment Received		$ 10,000,000
Milestone Payment Received in Cash		4,500,000
Milestone Payment Received in Equity Investment		5,500,000
Equity investment measure at fair value		4,730,000
Premium		770,000
Revenue		4,500,000
Transaction price allocated to performance obligations		$ 0
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone Payment Received	$ 15,000,000
Milestone Payment Received in Cash	6,750,000
Milestone Payment Received in Equity Investment	$ 8,250,000
Common shares, Issued	258,986
Common stock, par or stated value per share	$ 31.855
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligations						28,807,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Development Services Under the Initial Development Program for the DTCs [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligations				5,118,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments Receivable			1,067,500,000			1,067,500,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Sales Based Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments Receivable			$ 600,000,000			$ 600,000,000
Pacira BioSciences [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments				3,000,000
Pacira BioSciences [Member] | Asset Purchase Agreement [Member] | XEN402 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments				1,000,000
Milestone payment due on initiation of Phase 1b clinical trial				2,000,000
Pacira BioSciences [Member] | Asset Purchase Agreement [Member] | Eligible to Receive Development Milestone Payment [Member] | XEN402 [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments Receivable				5,000,000
Pacira BioSciences [Member] | Asset Purchase Agreement [Member] | Future Clinical Development And Global Regulatory Approval Milestone Payments [Member] | XEN402 [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments Receivable				40,750,000
Pacira BioSciences [Member] | Asset Purchase Agreement [Member] | Commercial Milestone Payments [Member] | XEN402 [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments Receivable				$ 75,000,000